Evidence map›Paper›PMID 28169190›Full record

ArticleEBioMedicine2017

Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis.

Michael J Kemna, Rosina Plomp, Pieter van Paassen, Carolien A M Koeleman, Bas C Jansen, Jan G M C Damoiseaux, Jan Willem Cohen Tervaert, Manfred Wuhrer

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Immunoglobulin G in aging and cancer.Frontiers in immunology · 2026
    Review
  5. Antibody glycosylation in neuroimmune diseases.Journal of translational medicine · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Glycobiology of rheumatic diseases.Nature reviews. Rheumatology · 2023
    Review
  17. Article
  18. The role ofFrontiers in immunology · 2023
    Review
  19. IgGBiomedicines · 2022
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Michael J KemnaCardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; Department of Internal Medicine, Division of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands.
Rosina PlompCentral Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, The Netherlands.
Pieter van PaassenCardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; Department of Internal Medicine, Division of Nephrology and Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands.
Carolien A M KoelemanCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Bas C JansenCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Jan G M C DamoiseauxCentral Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, The Netherlands.
Jan Willem Cohen TervaertCardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. Electronic address: jw.cohentervaert@maastrichtuniversity.nl.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
Maastricht University · NLNetherlands Metabolomics Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of our study is to investigate the Fc glycosylation profiles of both antigen-specific IgG targeted against proteinase 3 (PR3-ANCA) and total IgG as prognostic markers of relapse in patients with Granulomatosis with Polyangiitis (GPA).

methodsSeventy-five patients with GPA and a PR3-ANCA rise during follow-up were included, of whom 43 patients relapsed within a median period of 8 (2-16) months. The N-glycan at Asn297 of affinity-purified and denatured total IgG and PR3-ANCA was determined by mass spectrometry of glycopeptides in samples obtained at the time of the PR3-ANCA rise and at the time of the relapse or time-matched during remission.

resultsPatients with total IgG1 exhibiting low galactosylation or low sialylation were highly prone to relapse after an ANCA rise (HR 3.46 [95%-CI 1.73-6.96], p<0.0001 and HR 3.22 [95%-CI 1.52-6.83], p=0.002, respectively). In relapsing patients, total IgG1 galactosylation, sialylation and bisection significantly decreased and fucosylation significantly increased from the time of the PR3-ANCA rise to the relapse (p<0.0001, p=0.0087, p<0.0001 and p=0.0025), while the glycosylation profile remained similar in non-relapsing patients. PR3-ANCA IgG1 galactosylation, sialylation and fucosylation of PR3-ANCA IgG1 decreased in relapsing patients (p=0.0073, p=0.0049 and p=0.0205), but also in non-relapsing patients (p=0.0007, p=0.0114 and p=0.0002), while bisection increased only in non-relapsing patients (p<0.0001).

conclusionWhile Fc glycosylation profiles have been associated with clinically manifest autoimmune diseases, in the present study we show that low galactosylation and sialyation in total IgG1 but not PR3-ANCA IgG1 predicts disease reactivation in patients with GPA who experience an ANCA rise during follow-up. We postulate that glycosylation profiles may be useful in pre-emptive therapy studies using ANCA rises as guideline.

Indexed as

AdultAgedBiomarkersCase-Control StudiesFemaleGalactoseGlycoproteinsGranulomatosis with PolyangiitisHumansImmunoglobulin Fc FragmentsImmunoglobulin GMaleMiddle AgedMyeloblastinSialic AcidsBiomarkersGalactoseGlycoproteinsglycosylated IgGImmunoglobulin Fc FragmentsImmunoglobulin GMyeloblastinSialic AcidsGlycopeptideGlycosylationGranulomatosis with PolyangiitisImmunoglobulinMass spectrometryPR3-ANCA associated vasculitis

Identifiers

PMID28169190
PMCPMC5360573
OpenAlexW2579989558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.